Eagle Pharmaceuticals (EGRX) Upgraded to Buy by BidaskClub

Eagle Pharmaceuticals (NASDAQ:EGRX) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

Several other brokerages also recently issued reports on EGRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a research report on Friday, October 27th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Mizuho reissued a “sell” rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $63.67.

Shares of Eagle Pharmaceuticals (EGRX) traded up $0.74 during trading hours on Thursday, hitting $56.81. The stock had a trading volume of 255,249 shares, compared to its average volume of 200,448. The firm has a market capitalization of $847.72, a P/E ratio of 9.16 and a beta of 1.25. Eagle Pharmaceuticals has a 12 month low of $45.05 and a 12 month high of $97.15. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a return on equity of 62.60% and a net margin of 36.95%. research analysts predict that Eagle Pharmaceuticals will post 2.23 EPS for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in EGRX. Schwab Charles Investment Management Inc. grew its position in Eagle Pharmaceuticals by 2.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 37,053 shares of the specialty pharmaceutical company’s stock worth $2,924,000 after buying an additional 737 shares in the last quarter. Wells Fargo & Company MN grew its position in Eagle Pharmaceuticals by 20.2% during the second quarter. Wells Fargo & Company MN now owns 15,866 shares of the specialty pharmaceutical company’s stock worth $1,251,000 after buying an additional 2,663 shares in the last quarter. Alliancebernstein L.P. grew its position in Eagle Pharmaceuticals by 105.3% during the second quarter. Alliancebernstein L.P. now owns 29,770 shares of the specialty pharmaceutical company’s stock worth $2,349,000 after buying an additional 15,270 shares in the last quarter. Ameriprise Financial Inc. grew its position in Eagle Pharmaceuticals by 16.0% during the second quarter. Ameriprise Financial Inc. now owns 133,071 shares of the specialty pharmaceutical company’s stock worth $10,500,000 after buying an additional 18,335 shares in the last quarter. Finally, New York State Common Retirement Fund grew its position in Eagle Pharmaceuticals by 41.1% during the second quarter. New York State Common Retirement Fund now owns 51,503 shares of the specialty pharmaceutical company’s stock worth $4,063,000 after buying an additional 15,002 shares in the last quarter.

WARNING: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/11/eagle-pharmaceuticals-egrx-upgraded-to-buy-by-bidaskclub.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply